NASDAQ:PASG Passage Bio (PASG) Stock Price, News & Analysis $0.70 +0.06 (+9.32%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.63▼$0.7050-Day Range$0.64▼$1.0052-Week Range$0.58▼$1.79Volume189,512 shsAverage Volume270,225 shsMarket Capitalization$43.49 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Passage Bio alerts: Email Address Passage Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,083.7% Upside$8.33 Price TargetShort InterestHealthy3.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector437th out of 910 stocksBiological Products, Except Diagnostic Industry64th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingPassage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePassage Bio has only been the subject of 1 research reports in the past 90 days.Read more about Passage Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.67% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Passage Bio has recently decreased by 4.28%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PASG. Previous Next 2.4 News and Social Media Coverage News SentimentPassage Bio has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Passage Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PASG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Passage Bio is held by insiders.Percentage Held by Institutions53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Passage Bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Passage Bio are expected to grow in the coming year, from ($0.94) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Passage Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Passage Bio Stock (NASDAQ:PASG)Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More PASG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PASG Stock News HeadlinesSeptember 5 at 2:49 AM | americanbankingnews.comPassage Bio (NASDAQ:PASG) Coverage Initiated at Rodman & RenshawSeptember 4 at 3:08 PM | msn.comRodman & Renshaw Initiates Coverage of Passage Bio (PASG) with Buy RecommendationSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 30, 2024 | globenewswire.comPassage Bio to Present at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 10, 2024 | msn.comPassage Bio Reports Q2 2024 Financial Results and Business UpdatesAugust 8, 2024 | globenewswire.comPassage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business HighlightsAugust 3, 2024 | fr.investing.comPassage Bio risque d'être radiée de la cote du Nasdaq en raison du prix de son actionAugust 3, 2024 | msn.comPassage Bio Out-Licenses Rare Disease Programs to GEMMA BiotherapeuticsSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 1, 2024 | msn.comPassage Bio gains after licensing deal with GEMMA BioAugust 1, 2024 | globenewswire.comPassage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research CollaborationJuly 20, 2024 | markets.businessinsider.comExpanding Market and Promising Preclinical Results Bolster Buy Rating for Passage BioJuly 16, 2024 | globenewswire.comPassage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 PatientsJune 5, 2024 | globenewswire.comPassage Bio to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceMay 21, 2024 | globenewswire.comPassage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship AwardMay 15, 2024 | markets.businessinsider.comOptimistic Outlook for Passage Bio Amid Clinical and Financial Progress: Maintains Buy RatingMay 15, 2024 | msn.comPassage Bio Reports Promising Interim Data in FTD-GRN Treatment TrialMay 14, 2024 | investorplace.comPASG Stock Earnings: Passage Bio Beats EPS for Q1 2024See More Headlines Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PASG CUSIPN/A CIK1787297 Webwww.passagebio.com Phone267-866-0311FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$13.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,083.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.74% Return on Assets-52.29% Debt Debt-to-Equity RatioN/A Current Ratio7.67 Quick Ratio7.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book0.35Miscellaneous Outstanding Shares61,770,000Free Float58,990,000Market Cap$43.49 million OptionableOptionable Beta1.19 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. William Chou M.D. (Age 50)President, CEO & Director Comp: $945.73kMr. Edgar B. Cale Esq. (Age 60)J.D., General Counsel & Company Secretary Comp: $804.69kDr. Mark Forman M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $866.31kDr. James M. Wilson M.D. (Age 69)Ph.D., Co-Founder & Chief Scientific Advisor Ms. Kathleen Borthwick (Age 47)Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer Mr. Stuart M. HendersonSenior Vice President of Corporate Development & Investor RelationsEden FucciSenior Vice President of Technical OperationsDr. Sue Browne Ph.D.Senior Vice President of Research & DevelopmentDr. Karl Whitney Ph.D.Senior Vice President of Global Regulatory AffairsMore ExecutivesKey CompetitorsAligos TherapeuticsNASDAQ:ALGSGeneration BioNASDAQ:GBIOOutlook TherapeuticsNASDAQ:OTLKMediWoundNASDAQ:MDWDProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInsiders & InstitutionsLynx1 Capital Management LPBought 211,758 shares on 8/15/2024Ownership: 8.188%Renaissance Technologies LLCSold 79,950 shares on 8/9/2024Ownership: 1.826%Versant Venture Management LLCSold 933,352 shares on 8/8/2024Ownership: 6.532%Mark S FormanSold 1,638 sharesTotal: $1,588.86 ($0.97/share)Kathleen BorthwickSold 1,470 sharesTotal: $1,425.90 ($0.97/share)View All Insider TransactionsView All Institutional Transactions PASG Stock Analysis - Frequently Asked Questions How have PASG shares performed this year? Passage Bio's stock was trading at $1.01 at the beginning of the year. Since then, PASG shares have decreased by 30.3% and is now trading at $0.7040. View the best growth stocks for 2024 here. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) issued its earnings results on Thursday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.05. When did Passage Bio IPO? Passage Bio (PASG) raised $126 million in an IPO on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager. Who are Passage Bio's major shareholders? Top institutional shareholders of Passage Bio include Lynx1 Capital Management LP (8.19%), Versant Venture Management LLC (6.53%) and Renaissance Technologies LLC (1.83%). Insiders that own company stock include Orbimed Advisors Llc, Mark S Forman, Alexandros Fotopoulos, Kathleen Borthwick, Simona King, Sandip Kapadia and Bruce A Goldsmith. View institutional ownership trends. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX) and Gossamer Bio (GOSS). This page (NASDAQ:PASG) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
